Pharmaron

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Pharmaron, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Pharmaron please access flcube.comFineline Info & Tech (Flcube.com) provides you with comprehensive information about Pharmaron, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Pharmaron please access flcube.com

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers
CompanyDrug

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its three drug candidates – BL-M07D1, BL-M05D1, and izalontamab bretecan – have been granted Breakthrough Therapy Designation (BTD) by the Center…

Biokin's BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Haisco's HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

Haisco’s HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Pharmaron Posts 17.9% First‑Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand
Company

Pharmaron Posts 17.9% First‑Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand

Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200 M Deal
CompanyDeals

Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200 M Deal

CN Bio and Pharmaron Partner to Validate and Expand OOC Technology Applications
CompanyDeals

CN Bio and Pharmaron Partner to Validate and Expand OOC Technology Applications

CompanyDeals

Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services

CompanyDeals

Pharmaron to Sell Proteologix Stake in Upcoming Johnson & Johnson Acquisition

CompanyDeals

Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services

CompanyDeals

Pharmaron Secures UK Government Grant to Expand Viral Vector Manufacturing Facility

CompanyDeals

Lab Direct Raises USD 10M in Series A+ to Expand Digital Supply Chain Platform